 |
 |

Aspirin and Angiotensin-Converting Enzyme Inhibitors Among Elderly Survivors of Hospitalization for an Acute Myocardial Infarction
Harlan M. Krumholz, MD;
Ya-Ting Chen, PhD;
Yongfei Wang, MS;
Martha J. Radford, MD
Arch Intern Med. 2001;161:538-544.
Background Aspirin and angiotensin-converting enzyme (ACE) inhibitors are recommended
for secondary prevention after acute myocardial infarction (AMI), but several
studies have suggested that the combination of these medications may produce
a negative interaction.
Objective To evaluate the effect and interaction of aspirin and ACE inhibitors
on mortality among elderly patients who survived a hospitalization for AMI.
Methods We evaluated the effect and interaction of aspirin and ACE inhibitors
on mortality in patients aged 65 years and older who survived hospitalization
with a confirmed AMI who were ideal candidates for the therapies.
Results Among the 14 129 patients, 26% received aspirin only, 20% received
ACE inhibitors only, 38% received both, and 16% received neither at discharge.
In the multivariate analysis, patients who received both aspirin and ACE inhibitors
alone had a significantly lower 1-year mortality (adjusted risk ratio [ARR],
0.86 [95% confidence interval (CI), 0.78-0.95] vs 0.85 [95% CI, 0.77-0.93],
respectively) compared with patients who received neither aspirin nor ACE
inhibitors at discharge. Prescribing both aspirin and ACE inhibitors was associated
with a slightly lower risk of mortality (ARR, 0.81; 95% CI, 0.74-0.88) than
that seen in aspirin-only or ACE inhibitoronly groups, but the difference
was not significantly different from the use of either medication alone.
Conclusions The benefit of ACE inhibitors and aspirin is consistent with what would
be expected from overall results of randomized trials; prescribed together,
the effect is slightly greater than with either one alone, but not significantly
or substantially so.
From the Section of Cardiovascular Medicine (Drs Krumholz and Radford
and Mr Wang), Section of Chronic Disease Epidemiology, Department of Epidemiology
and Public Health (Dr Krumholz), and Department of Medicine (Dr Chen), Yale
University School of Medicine, and the YaleNew Haven Hospital Center
for Outcomes Research and Evaluation (Drs Krumholz and Radford), New Haven,
Conn; and Qualidigm, Middletown, Conn (Drs Krumholz and Radford). Dr Chen
is now with Merck and Co, Inc, West Point, Pa.
Corresponding author and reprints: Harlan M. Krumholz, MD, Yale University
School of Medicine, 333 Cedar St, PO Box 208025, New Haven, CT 06520-8025
(e-mail: harlan.krumholz{at}yale.edu).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2001;161(4):617-618.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Acute Coronary Care in the Elderly, Part II: ST-Segment-Elevation Myocardial Infarction: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology
Alexander et al.
Circulation 2007;115:2570-2589.
ABSTRACT
| FULL TEXT
Aspirin Use and Outcomes in a Community-Based Cohort of 7352 Patients Discharged After First Hospitalization for Heart Failure
McAlister et al.
Circulation 2006;113:2572-2578.
ABSTRACT
| FULL TEXT
Insulin-Sensitizing Antihyperglycemic Drugs and Mortality After Acute Myocardial Infarction: Insights from the National Heart Care Project
Inzucchi et al.
Diabetes Care 2005;28:1680-1689.
ABSTRACT
| FULL TEXT
Aspirin Does Not Adversely Affect Survival in Patients With Stable Congestive Heart Failure Treated With Angiotensin-Converting Enzyme Inhibitors
Aumegeat et al.
Chest 2003;124:1250-1258.
ABSTRACT
| FULL TEXT
Drug Therapy for Prevention of Recurrent Myocardial Infarction
van der Elst et al.
The Annals of Pharmacotherapy 2003;37:1465-1477.
ABSTRACT
| FULL TEXT
Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: rationale and clinical relevance
Meune et al.
Journal of Renin-Angiotensin-Aldosterone System 2003;4:149-154.
ABSTRACT
Aspirin-Angiotensin-Converting Enzyme Inhibitor Coadministration and Mortality in Patients With Heart Failure: A Dose-Related Adverse Effect of Aspirin
Guazzi et al.
Arch Intern Med 2003;163:1574-1579.
ABSTRACT
| FULL TEXT
Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function
Zhu et al.
Journal of Renin-Angiotensin-Aldosterone System 2003;4:31-37.
ABSTRACT
Aspirin Use and Counseling About Aspirin Among Patients With Diabetes
Krein et al.
Diabetes Care 2002;25:965-970.
ABSTRACT
| FULL TEXT
Interaction Between Angiotensin-Converting Enzyme Inhibitors and Aspirin
Etminan et al.
Arch Intern Med 2001;161:2048-2049.
FULL TEXT
|